ACRS
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
$ACRS reports strong financial position and progress in clinical programs for Q1 2023
Aclaris Therapeutics reported Q1 2023 financial results, with $204.4m in cash and marketable securities as of March 31, 2023. They issued 3.4 million shares under their ATM facility for $26.7m in net proceeds, closed in April 2023. Aclaris' cash reserves and sales under the ATM facility are expected to fund their operations through the end of 2025. They have a solid R&D engine developing drugs for immuno-inflammatory diseases, including rheumatoid and psoriatic arthritis. While their MK2 inhibitor for hidradenitis suppurativa showed no positive efficacy results, the drug performed mechanistically as expected, contributing to a sturdy financial position.
4mo ago
$ACRS